Zhang Jianzhi, Zhu Hao, Liu Wentao, Miao Ji, Mao Yonghuan, Li Qiang
Department of General Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.
Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
Front Oncol. 2025 Apr 16;15:1532924. doi: 10.3389/fonc.2025.1532924. eCollection 2025.
Precision medicine has brought revolutionary changes to the diagnosis and treatment of cancer patients, and is currently a hot and challenging research topic. Currently, the treatment regimens for most colorectal cancer (CRC) patients are mainly determined by several biomakers, including Microsatellite Instability (MSI), RAS, and BRAF. However, the roles of promising biomarkers such as HER-2, consensus molecular subtypes (CMS), and circulating tumor DNA (ctDNA) in CRC are not yet fully clear. Therefore, it is urgent to explore the potential of these emerging biomarkers in the diagnosis and treatment of CRC patients. In this paper, we discuss recent advances in CRC biomarkers, especially clinical data, and focus on the roles of biomarkers in prognosis, prediction, treatment strategies, and the intrinsic connections with clinical pathological features, hoping to promote better precision medicine for colorectal cancer.
精准医学给癌症患者的诊断和治疗带来了革命性变化，目前是一个热门且具有挑战性的研究课题。目前，大多数结直肠癌（CRC）患者的治疗方案主要由几种生物标志物决定，包括微卫星不稳定性（MSI）、RAS和BRAF。然而，有前景的生物标志物如HER-2、共识分子亚型（CMS）和循环肿瘤DNA（ctDNA）在CRC中的作用尚未完全明确。因此，迫切需要探索这些新兴生物标志物在CRC患者诊断和治疗中的潜力。在本文中，我们讨论了CRC生物标志物的最新进展，特别是临床数据，并重点关注生物标志物在预后、预测、治疗策略以及与临床病理特征的内在联系方面的作用，希望能促进更好的结直肠癌精准医学。
